OLMA

Neutral

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Olema Oncology has announced a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in comb...

The Manila Times 7 mins ago 0

Bullish

New prostate cancer trial pairs Olema drug with Bayer’s NUBEQA

Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to evaluate its KAT6 inhibitor OP-3136, in combination with Ba...

Stock Titan 1 min ago 0